📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Module 1 (US) — Application Summary (OBX-319)

Document ID: M1-IND
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): eCTD US regional

Application Summary — OBX-319

Sponsor: Virtual Biopharma Inc.. Investigational product: OBX-319 (bispecific monoclonal antibody). Proposed indication: Systemic Lupus Erythematosus (moderate-to-severe active). Pivotal study: OBX319-301 (Phase 3).

OBX-319 is a humanized IgG1 bispecific monoclonal antibody engineered to co-engage CD19 and CD20 on the B-lymphocyte surface, delivering broad, dual-antigen B-cell depletion across the B-lineage (CD19 is expressed from the pro-B through plasmablast stages; CD20 spans pre-B through memory B cells). The molecule is expressed by fed-batch culture of a recombinant Chinese hamster ovary (CHO) host cell line and purified through a Protein A affinity capture step followed by orthogonal polishing chromatography and dedicated viral clearance operations. The product is presented for subcutaneous administration. The mechanistic rationale in systemic lupus erythematosus (SLE) is deeper and more uniform depletion of autoreactive B cells — including populations incompletely covered by single-target agents — with consequent reduction of autoantibody production and restoration of complement homeostasis.

This IND supports the conduct of pivotal Phase 3 study OBX319-301. The sponsor intends to seek licensure of OBX-319 as a biological product under section 351 of the Public Health Service Act and 21 CFR Part 601 (Biologics License Application). Chemistry, manufacturing and controls, nonclinical, and clinical development are conducted in accordance with the applicable ICH guidances for biotechnology-derived products, including Q5A(R2) (viral safety evaluation), Q5C (stability testing of biotechnological/biological products), Q6B (specifications and analytical procedures), and S6(R1) (preclinical safety evaluation of biotechnology-derived pharmaceuticals). Consistent with the large-molecule nature of the product, dedicated ICH S7B/E14 hERG and thorough-QT assessments and ICH S2 genotoxicity and carcinogenicity studies are not warranted.

Nonclinical basis

The nonclinical programme (cynomolgus monkey as the sole pharmacologically relevant species (no rodent cross-reactivity)) established the safety margins supporting the clinical doses.

Species selection follows directly from target biology: OBX-319 binds the cynomolgus CD19 and CD20 orthologues and produces the expected B-cell-depleting pharmacology in that species, whereas it does not bind the rodent orthologues with pharmacological relevance. In accordance with ICH S6(R1), the cynomolgus monkey therefore serves as the single relevant toxicology species, and a single-species repeat-dose programme is scientifically justified. GLP-compliant repeat-dose subcutaneous toxicology studies with a recovery phase characterised the on-target pharmacology — marked but reversible depletion of peripheral and tissue B cells with attendant reductions in circulating immunoglobulins — and defined the exposure margins referenced above. Core safety pharmacology endpoints (cardiovascular, respiratory, and central nervous system) were integrated into the repeat-dose design rather than conducted as standalone studies.

The pharmacokinetics are governed by target-mediated drug disposition (TMDD): nonlinear, target-mediated clearance predominates at low concentrations, transitioning to approximately linear disposition once B-cell targets are saturated. Tissue cross-reactivity was assessed using human and cynomolgus tissue panels. Anti-drug antibody responses were monitored in the toxicology species; as is typical for humanized biologics, animal immunogenicity is of limited predictive value for the clinic but was accounted for in the interpretation of exposure. Reproductive and developmental risk was evaluated with attention to the class expectation that IgG1 antibodies cross the placenta during the second and third trimesters, with the potential for transient B-cell depletion in the neonate. Consistent with ICH S6(R1) and the molecule's modality, genotoxicity, carcinogenicity, hERG, and thorough-QT studies were not conducted.

Clinical summary

OBX319-301 is a randomized, double-blind, placebo-controlled Phase 3 study in which 480 adults with moderate-to-severe active SLE were randomized 1:1:1 to OBX-319 High, OBX-319 Low, or placebo (162 / 158 / 160), each administered on a background of standard-of-care therapy for 52 weeks. The enrolled population had active disease at entry, with a mean baseline SLEDAI-2K of approximately 11.

The primary endpoint was the proportion of patients achieving an SRI-4 response together with attainment of low disease activity (SLEDAI-2K ≤ 4) at Week 52:

Arm	Primary responders (SRI-4 / SLEDAI-2K ≤ 4) @ Wk 52
OBX-319 High	52.4% (76/145)
OBX-319 Low	33.8% (49/145)
Placebo	6.0% (9/150)

Both active doses were superior to placebo. The key secondary endpoint, LS-mean change from baseline in SLEDAI-2K at Week 52, was consistent with the primary result:

Arm	N	LS-mean Δ SLEDAI-2K @ Wk 52 (points)	Diff vs placebo (95% CI)	p
OBX-319 High	162	-6.37	-2.91 (-3.12, -2.69)	0.0000
OBX-319 Low	158	-5.62	-2.17 (-2.38, -1.95)	0.0000
Placebo	160	-3.46	— (reference)	—

Pharmacodynamic findings support the proposed dual-targeting mechanism: both active arms produced near-complete peripheral CD19+ B-cell depletion (approximately 210 → 7 cells/µL), which was not observed with placebo, accompanied by declining anti-dsDNA titres and normalisation of complement C3 and C4 in responders. Systemic exposure and clinical response were interpreted in the context of TMDD, and anti-drug antibodies were monitored throughout as an expected consideration for this modality.

The observed and anticipated safety profile is consistent with the pharmacological class of B-cell-depleting agents. Serious and opportunistic infections and hypogammaglobulinaemia are the principal identified risks and are managed through screening, vaccination where appropriate, and monitoring of immunoglobulin levels; injection-site and administration reactions and immunogenicity are expected and are monitored under the study's risk-management measures. No thyroid-related boxed warning is applicable to OBX-319, that being a consideration for an unrelated pharmacological class.

The application requests review under the applicable regional pathway. The sponsor intends to file a Biologics License Application for OBX-319 under 21 CFR Part 601, supported by the CHO-based manufacturing and control strategy, the cynomolgus nonclinical package, and the Phase 3 efficacy, pharmacodynamic, and safety results summarised above.